India, Nov. 4 -- What have been some of the major developments at Biodeal Pharma in 2026 that set the tone for the company's growth in the next few years?

2026 has been a defining year for Biodeal Pharmaceuticals as we have strengthened both our financial foundation and manufacturing capabilities. These developments position us to build on our established expertise in specialty formulations and pursue opportunities in more technically complex segments.

The strategic investment of Rs 385 crore from RMB Capitalworks provides us with a stronger platform to invest in our next phase of growth. We also completed the full redemption of Piramal Alternatives' Rs 110 crore investment, delivering an IRR of over 20 per cent. This marks an important...